Adjuvant therapy after surgery in pancreatic cancer:Research progress
LIU Yue-ze
ZHANG Meng-gang
ZHANG Tai-ping
Abstract：Postoperative adjuvant therapy for pancreatic cancer has become the core component of comprehensive management.The mainstream regimens include gemcitabine monotherapy,gemcitabine combined with capecitabine,modified FOLFIRINOX,and gemcitabine combined with S-1.Full-dose and full-cycle chemotherapy is crucial to improving survival benefits for patients.Biomarkers such as circulating tumor cells(CTCs)and circulating tumor DNA(ctDNA),as well as technologies such as patient-derived organoid(PDO)drug sensitivity testing and artificial intelligence-assisted transcriptomic analysis,provide important support for precise and individualized adjuvant therapy.Adjuvant radiotherapy,targeted therapy,and immunotherapy show potential in high-risk patients.Future research should focus on head-to-head comparisons of multiple regimens and molecular stratification guidance to optimize combination therapy strategies and continuously enhance survival benefits for patients.
Keywords：pancreatic cancerpostoperative adjuvant therapychemotherapytargeted therapy
Publication Date：2025-06-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 645-649 )